LTX-109
- Generic Name
- LTX-109
- Drug Type
- Small Molecule
- Chemical Formula
- C43H69N11O3
- CAS Number
- 1166254-80-3
- Unique Ingredient Identifier
- HO813QDF65
- Background
LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.
Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
- Conditions
- Nasal Decolonization of Staphylococcus Aureus
- Interventions
- Drug: Vehicle gel, 4 + 4 applications or 4 + 2 applications
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 27
- Registration Number
- NCT05889351
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 60
- Registration Number
- NCT04854928
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus
- Conditions
- Nasal Decolonization of Staphylococcus Aureus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 15
- Registration Number
- NCT04767321
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
LTX-109 as Treatment for Hidradenitis Suppurativa
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 11
- Registration Number
- NCT04756336
- Locations
- 🇳🇴
University Hospital of North Norway, Tromsø, Norway
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
- Conditions
- Non-bullous Impetigo
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 210
- Registration Number
- NCT01803035
- Locations
- 🇩🇴
Institute of Dermatology and and Skin Surgery Dr. Hubert Bogaert Diaz, Santo Domingo, Dominican Republic
🇩🇴Dr. Robert Reid Cabral Children Hospital, Santo Domingo, Dominican Republic
A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection
- Conditions
- Gram-positive, Skin InfectionsMild Eczema/DermatosesAtopic Dermatitis
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 24
- Registration Number
- NCT01223222
- Locations
- 🇭🇺
Debreceni Egyetem Orvos-és Egészségtudományi, Debrecen, Hungary
🇭🇺Pécsi Tudományegyetem általános Orvostudom´nyi Centum, Pécs, Hungary
🇭🇺Miskolci Semmelweis Ignác Egészegügyi Központ és, Miskolc, Hungary
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 24
- Registration Number
- NCT01158235
- Locations
- 🇸🇪
Skåne University Hospital, Malmö, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.